Schreiber H - Search Results

1

Cytokines and cancer: experimental systems.

Blankenstein T, Rowley DA, Schreiber H. Blankenstein T, et al. Among authors: schreiber h. Curr Opin Immunol. 1991 Oct;3(5):694-8. doi: 10.1016/0952-7915(91)90098-l. Curr Opin Immunol. 1991. PMID: 1755987 Review.

2

Targeting cancer-specific mutations by T cell receptor gene therapy.

Blankenstein T, Leisegang M, Uckert W, Schreiber H. Blankenstein T, et al. Among authors: schreiber h. Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Curr Opin Immunol. 2015. PMID: 25728991 Free PMC article. Review.

3

The role of stroma in immune recognition and destruction of well-established solid tumors.

Yu P, Rowley DA, Fu YX, Schreiber H. Yu P, et al. Among authors: schreiber h. Curr Opin Immunol. 2006 Apr;18(2):226-31. doi: 10.1016/j.coi.2006.01.004. Epub 2006 Feb 3. Curr Opin Immunol. 2006. PMID: 16459066 Review.

4

Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.

Koeppen H, Acena M, Drolet A, Rowley DA, Schreiber H. Koeppen H, et al. Among authors: schreiber h. Eur J Immunol. 1993 Nov;23(11):2770-6. doi: 10.1002/eji.1830231108. Eur J Immunol. 1993. PMID: 8223853

5

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H. Binder DC, et al. Among authors: schreiber h. Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058. Cancer Immunol Res. 2013. PMID: 24455752 Free PMC article.

6

C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum.

Beck C, Schreiber K, Schreiber H, Rowley DA. Beck C, et al. Among authors: schreiber k, schreiber h. Eur J Immunol. 2003 Jan;33(1):19-28. doi: 10.1002/immu.200390003. Eur J Immunol. 2003. PMID: 12594828 Free article.

7

Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity.

Mullen CA, Rowley DA, Schreiber H. Mullen CA, et al. Among authors: schreiber h. Cell Immunol. 1989 Mar;119(1):101-13. doi: 10.1016/0008-8749(89)90227-x. Cell Immunol. 1989. PMID: 2522025

8

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. Torre-Amione G, et al. Among authors: schreiber h. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486-90. doi: 10.1073/pnas.87.4.1486. Proc Natl Acad Sci U S A. 1990. PMID: 2137615 Free PMC article.

9

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Singh S, et al. Among authors: schreiber h. J Exp Med. 1992 Jan 1;175(1):139-46. doi: 10.1084/jem.175.1.139. J Exp Med. 1992. PMID: 1309851 Free PMC article.

10

Multiple cancers. Tumor burden permits the outgrowth of other cancers.

Mullen CA, Urban JL, Van Waes C, Rowley DA, Schreiber H. Mullen CA, et al. Among authors: schreiber h. J Exp Med. 1985 Nov 1;162(5):1665-82. doi: 10.1084/jem.162.5.1665. J Exp Med. 1985. PMID: 3877140 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

848 results

Search Page

Filters